Filgotinib + Adalimumab
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Oct 1, 2022 → Oct 1, 2025
NCT ID
NCT05502731About Filgotinib + Adalimumab
Filgotinib + Adalimumab is a approved stage product being developed by Galapagos for Rheumatoid Arthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05502731. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05502731 | Approved | UNKNOWN |
Competing Products
20 competing products in Rheumatoid Arthritis